Our vision is to be a trusted leader in changing the practice of medicine. A big part of gaining this trust is being transparent – being open and clearly disclosing what we do, how we work, where we are successful. This applies across all aspects of our business around the world.
In order to allow everyone to get a better look at our business and how we operate, we publish several key pieces of information. To find publications related to the Novartis Foundation, visit their website. To access publications from prior years, visit our Reporting Archive.
Novartis in Society Integrated Report
We publish an annual Novartis in Society Integrated Report, which combines our former Novartis in Society ESG Report and Annual Review. The report highlights progress against our strategy and describes how we create value for our stakeholders. It is intended for all Novartis stakeholders, particularly shareholders, investors, and environmental, social and governance (ESG) professionals.
Reporting Criteria for Novartis in Society Integrated Report
This document provides definitions, methodologies and assumptions for assured ESG performance indicators in the Novartis in Society Integrated Report 2022.
Novartis Environmental, Social and Governance (ESG) Index
We have created the Novartis ESG Index to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.
UN Global Compact Communication on Progress
As an original signatory of the UN Global Compact (UNGC) in 2000, we are committed to sharing our progress in implementing the 10 principles of the compact. We publish a Communication on Progress annually in the first quarter of each year.
Payments to Healthcare Professionals
Novartis seeks to collaborate with Healthcare Professionals and Healthcare Organizations in the interest of patients. As an industry we make payments or ”transfers of value” to Healthcare Professionals and Organizations to compensate them for the time spent working with us. In several countries, we publish payments to Healthcare Professionals and Organizations in line with local laws or regulations.
Patient Organization Funding
Novartis works with many organizations that advocate for patients around the world. These organizations play a crucial role by informing and supporting patients, as well as safeguarding the rights of patients and caregivers. Each year we disclose our relationships with patient organizations online.
Public Policy & Advocacy
Novartis actively participates in public policy debates affecting healthcare and our business. This includes engaging in constructive dialogue with policymakers and other external stakeholders with the intent to represent the perspective of Novartis in the policy making process, as well as making financial contributions to support political dialogue on issues of relevance to the company.
Modern slavery statement
Novartis is committed to conducting our business in a manner that respects the rights and dignity of all people that may be affected by our business activities. Each year, we submit a statement that describes the activities we have undertaken to strengthen our processes and better understand the risks of modern slavery and human trafficking in our global operations and supply chains.
Novartis was one of the first international companies to implement a commitment to pay a living wage to all of its employees.
Employee safety is an integral part of an employer’s responsibility. Novartis Group companies are committed to providing our associates with safe workplaces.
Animals and research
Novartis needs animal research to find innovative, safe and life-saving medicines for patients. We are committed to transparent reporting of the numbers of animals needed for research and development purposes.
Clinical trial results disclosure
Novartis informs the public about the results of its interventional clinical trials for innovative compounds, regardless of the outcome. The results of Novartis clinical trials are made publicly available through peer-reviewed publications and posting of results on the Novartis clinical trial results database and other online public databases.
We take our responsibility to protect the environment seriously. As part of that commitment, each year we transparently disclose our strategy and our performance across multiple documents.
Download the Novartis 2030 Environmental Sustainability Strategy (PDF 16.3 MB)
See our 2022 environmental performance indicators here
Conflict minerals report
We disclose annually to the US Securities and Exchange Commission our use of certain minerals and their origins.
Download the SEC Form SD and Conflict Minerals Report 2021 (PDF 0.3 MB)
Novartis positions on key issues
As part of our ongoing commitment to transparency, we publish our positions on various issues affecting our business.
Codes, policies and guidelines
We publish an updated list of our major codes, policies and guidelines that govern the company’s activities.